TAK-438 Enters Phase II Clinical Trialsfor the Treatment of Reflux Esophagitis
TAK-438, originated by Takeda, is a potassium-competitive acid blocker that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+,K+-ATPase; it is a completely different mechanism of action from conventional proton pump inhibitors (“PPIs”). It is anticipated to have a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs.
“We expect TAK-438 to have greater acid suppression which may provide better clinical efficacy than PPIs which are widely used to treat acid-related diseases,” said Nancy Joseph-Ridge, M.D., General Manager, Pharmaceutical Development Division of Takeda. “We will continue the development of TAK-438 so that we might be able to offer it to patients as an optimal treatment option for the acid-related diseases, including reflux esophagitis, as quickly as possible.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.